GlassScriptPhysician profile
Francis L Mccafferty
NPI 1417997339
$18,114.79
in general payments reported to CMS, 2019-2025
44 companies · $3,255 in 2025
The $3,255 reported for 2025 was more than what 78% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,483 · 2020: $1,371 · 2021: $1,415 · 2022: $1,695 · 2023: $1,619 · 2024: $2,277 · 2025: $3,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,005 · Education: $92.92 · Consulting Fee: $52.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,004.94 |
| Education | $92.92 |
| Consulting Fee | $52.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $6,190.45 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,596.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,550.04 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,491.44 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $1,094.74 | 2020-2025 | Takhzyro, Hyqvia, Cuvitru |
| Csl Behring | $978.26 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $575.10 | 2019-2025 | |
| Pfizer INC. | $566.59 | 2019-2025 | |
| Amgen INC. | $412.26 | 2021-2025 | Tezspire |
| Octapharma USA, INC. | $379.66 | 2020-2023 | Cutaquig |
| Covis Pharma Gmbh | $355.78 | 2020-2022 | |
| Genentech USA, INC. | $339.72 | 2019-2025 | Xolair |
| Grifols USA, LLC | $338.63 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Kaleo, INC. | $278.89 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $255.11 | 2019-2023 |
Show all 42 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Mccafferty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.